Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Other product development or post-marketing obligations required by the FDA
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment

Other product development or post-marketing obligations required by the FDA

3 evidence topics · 1 source

Postmarketing commitment on reference standard qualification

“We remind you of your postmarketing commitment: 5036-1 Implement a two-tiered reference standard system by qualifying a working reference standard. Submit the qualification report(s) and requalification protocol for the working reference standard in a Prior Approval Supplement to the BLA.” (opens the source at this quote in a new tab)
“The timetable you submitted on July 17, 2026, states that you will conduct this study according to the following schedule: Final Report Submission: 7/2027” (opens the source at this quote in a new tab)

Pediatric study waiver

“We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable as the conditions rarely or never occur in pediatrics.” (opens the source at this quote in a new tab)

No advisory committee referral

“Your application for Lytenava was not referred to an FDA advisory committee because this biologic is not the first in its class.” (opens the source at this quote in a new tab)